These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 19662921)

  • 1. Opioid risk management: understanding FDA mandated risk evaluation and mitigation strategies (REMS).
    Sloan PA
    J Opioid Manag; 2009; 5(3):131-3. PubMed ID: 19662921
    [No Abstract]   [Full Text] [Related]  

  • 2. Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management.
    Peppin JF; Coleman JJ; Kirsh KL
    Issues Law Med; 2011; 27(2):91-119. PubMed ID: 22372206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.
    Nicholson SC; Evanyo K; Salinas GD; Roepke N; Burton BS; Susalka D
    J Opioid Manag; 2012; 8(4):212-6. PubMed ID: 22941848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Food and Drug Administration opioid Risk Evaluation and Mitigation Strategy.
    Lipman AG
    J Pain Palliat Care Pharmacother; 2009; 23(3):219-21. PubMed ID: 19670017
    [No Abstract]   [Full Text] [Related]  

  • 5. Rehabilitating opioid regulation: a prescription for the FDA's next proposal of an opioid risk evaluation and mitigation strategy (REMS).
    Homenko H
    Health Matrix Clevel; 2012; 22(1):273-313. PubMed ID: 22616548
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice.
    Gudin J
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):136-43. PubMed ID: 22764852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. REMS; red tape, or a remedy for opioid abuse?
    Porada S
    J Fam Pract; 2011 Sep; 60(9 Suppl):S55-62. PubMed ID: 22442761
    [No Abstract]   [Full Text] [Related]  

  • 8. Shared risk evaluation mitigation strategy for all immediate-release transmucosal fentanyl dosage forms.
    Food And Drug Administration, Public Health Service, U.S. Department Of Health And Human Services
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):123-6. PubMed ID: 22764848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.
    Stanos S
    Phys Sportsmed; 2012 Nov; 40(4):12-20. PubMed ID: 23306411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS).
    Nelson LS; Perrone J
    JAMA; 2012 Aug; 308(5):457-8. PubMed ID: 22851109
    [No Abstract]   [Full Text] [Related]  

  • 11. Foundations of opioid risk management.
    Katz NP; Adams EH; Benneyan JC; Birnbaum HG; Budman SH; Buzzeo RW; Carr DB; Cicero TJ; Gourlay D; Inciardi JA; Joranson DE; Kesslick J; Lande SD
    Clin J Pain; 2007 Feb; 23(2):103-18. PubMed ID: 17237659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Food and Drug Administration risk evaluation and mitigation strategy.
    Craig DS
    J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):145-8. PubMed ID: 20504137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Narcotic pain relievers: are you using them correctly?
    Johns Hopkins Med Lett Health After 50; 2012 Nov; 24(10):1-2. PubMed ID: 23362527
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA actions to prevent prescription drug abuse.
    Jeske AH
    Tex Dent J; 2005 Jul; 122(7):634-45. PubMed ID: 16152888
    [No Abstract]   [Full Text] [Related]  

  • 15. Opioid therapy and prescription drug diversion.
    Burgess FW; Pawasauskas J
    Med Health R I; 2008 Sep; 91(9):268-70. PubMed ID: 18834042
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA remodels REMS for opioid medications.
    Stone A
    ONS Connect; 2012 Sep; 27(9):18. PubMed ID: 23008909
    [No Abstract]   [Full Text] [Related]  

  • 17. Blueprint for prescriber continuing education program.
    Center For Drug Evaluation And Research Food And Drug Administration
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):127-30. PubMed ID: 22764849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pain: the doctor's dilemma.
    Phelps GL
    Tenn Med; 2011 Apr; 104(4):7-8. PubMed ID: 21560903
    [No Abstract]   [Full Text] [Related]  

  • 19. Pain treatment, drug diversion, and the casualties of war.
    Burgess F
    Pain Med; 2006; 7(6):474-5. PubMed ID: 17112360
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context.
    Leiderman DB
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S9-S13. PubMed ID: 19307069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.